Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1997-2-27
|
| pubmed:abstractText |
Systemic fungal infections (SFI) in patients receiving high-dose chemotherapy (HDC) are a frequent cause of morbidity and mortality. Preclinical studies have reported augmented antifungal activity of monocytes, macrophage cells, and neutrophils exposed to certain colony-stimulating factors (CSF), including GM-CSF. We conducted a retrospective descriptive epidemiologic study to examine the characteristics of 145 consecutive patients receiving HDC administered with or without autologous stem cell transplantation (ASCT) and who subsequently received either GM-CSF and G-CSF, G-CSF alone, GM-CSF +/- IL-3 or no CSF. The analysis of this patient population sought to define the incidence of SFI and its relationship to therapy with monocyte/macrophage-stimulating (MMS group) cytokines (GM-CSF and G-CSF; GM-CSF +/- IL-3) or to cytokines which do not result in monocyte/macrophage stimulation (NMMS group, G-CSF alone or no CSF). Risk factors for the development of SFI were balanced between the MMS (n = 70) and NMMS (n = 75) groups. Two patients (2.9%) in the MMS and nine patients (12%) in the NMMS groups developed SFI. The risk ratio for developing SFI in the NMMS group compared to the MMS group was 4.20 (P = 0.023). This relationship was confounded, however, by the diagnosis of hematologic tumor or solid tumor (RR = 3.15, P = 0.082). SFI was the primary cause or major contributing factor in five of the 10 total deaths in our study population. Four SFI-related deaths occurred in the NMMS group and one SFI-related death occurred in the MMS group. Our data suggest a protective role for GM-CSF, IL-3 or other MMS cytokines in preventing SFI in patients receiving HDC. This should be further investigated as a potential complementary approach to conventional strategies in antifungal prophylaxis for patients receiving HDC.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte Colony-Stimulating...,
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte-Macrophage...,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-3,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0268-3369
|
| pubmed:author |
pubmed-author:AdkinsD RDR,
pubmed-author:AuberryS ESE,
pubmed-author:BowersC ECE,
pubmed-author:DunphyF RFR,
pubmed-author:HarrisonB RBR,
pubmed-author:McIntyreWW,
pubmed-author:NiemeyerRR,
pubmed-author:PetersB GBG,
pubmed-author:PetruskaP JPJ,
pubmed-author:SpitzerGG,
pubmed-author:VelasquezW SWS,
pubmed-author:VrahnosDD
|
| pubmed:issnType |
Print
|
| pubmed:volume |
18
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
93-102
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8832001-Adult,
pubmed-meshheading:8832001-Aged,
pubmed-meshheading:8832001-Aged, 80 and over,
pubmed-meshheading:8832001-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8832001-Bone Marrow Diseases,
pubmed-meshheading:8832001-Disease Susceptibility,
pubmed-meshheading:8832001-Female,
pubmed-meshheading:8832001-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:8832001-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:8832001-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:8832001-Humans,
pubmed-meshheading:8832001-Immunity, Cellular,
pubmed-meshheading:8832001-Incidence,
pubmed-meshheading:8832001-Interleukin-3,
pubmed-meshheading:8832001-Male,
pubmed-meshheading:8832001-Middle Aged,
pubmed-meshheading:8832001-Mycoses,
pubmed-meshheading:8832001-Neoplasms,
pubmed-meshheading:8832001-Recombinant Proteins,
pubmed-meshheading:8832001-Retrospective Studies,
pubmed-meshheading:8832001-Risk Factors
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis.
|
| pubmed:affiliation |
Department of Pharmacy, Saint Louis University Hospital, MO 63110-0250, USA.
|
| pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't
|